slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
216,691-216,720 of 319,975
19
Includes a swimmer plot (onco-plot) and a summary table of best overall response (BOR) metrics.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
20
The slide uses a timeline to track treatment milestones and CT scans to show tumor reduction from baseline to complete response.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
21
Includes a swimmer plot (left) and a summary table (right) with clinical trial metrics.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Loop · Before After1 hit
22
The slide outlines a clinical trial protocol with three distinct cohorts and specific dosing schedules.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
23
Clinical trial design diagram showing randomization, arms, dosing schedules, and endpoints.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
24
The slide uses a hub-and-spoke diagram for the mechanistic combinations.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
25
The slide outlines the clinical strategy for optimizing nemvaleukin dosing, referencing specific clinical trials (ARTISTRY-3 and ARTISTRY-6).Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
26
Alkermes | Investor Presentation Deck | 37 slidesAlkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
27
The slide uses a process diagram to show the IL-18 signaling cascade (IL-18 -> MYD88 -> IRAK -> NFkB -> IFNy) and a numbered list to detail its immunomodulatory functions.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
28
Uses a combination of a scatter plot and biological mechanism diagrams to illustrate the inhibitory effect of IL-18BP.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
29
Uses a before-after-bridge framework to illustrate the mechanism of action for the therapeutic candidate.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
30
Data shows that while WT IL-18 is inhibited by IL-18BP, the variants are resistant to this inhibition.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
31
The slide uses a diagram to illustrate the activation of immune cells (NKT, NK, CD4, CD8) by IL-12, leading to IFN-gamma production and subsequent downstream effects.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
32
The slide uses a process flow diagram to explain the therapeutic mechanism.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
33
Includes a bar chart showing dose-dependent PD response in a mouse model and a schematic of the split IL-12 mechanism.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
34
Alkermes | Investor Presentation Deck | 37 slidesAlkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
35
Includes a footnote regarding patient enrollment for clinical milestones.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Financials1 hit
36
Uses a numbered list format to highlight key company facts.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Financials1 hit
37
Alkermes | Investor Presentation Deck | 37 slidesAlkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
01
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations 1 hit
02
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations 1 hit
03
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Problem1 hit
04
The slide highlights significant growth in revenue and net income metrics year-over-year.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Problem1 hit
05
Includes a blue box highlight around the Q3'23 column.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations 1 hit
06
Includes both GAAP and non-GAAP projections, plus specific product revenue breakdowns.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations 1 hit
07
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
08
The chart illustrates the revenue contribution of four specific products (VIVITROL, ARISTADA, VUMERITY, LYBALVI) over time.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
09
Includes a disclaimer regarding the forward-looking nature of the expectations.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
10
The chart tracks TRx (Total Prescriptions) over 101 weeks.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
11
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit